Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $3.98 Million - $6.76 Million
-367,113 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$13.07 - $18.84 $81,752 - $117,844
-6,255 Reduced 1.68%
367,113 $6.59 Million
Q2 2021

Aug 16, 2021

SELL
$16.52 - $20.4 $356,187 - $439,844
-21,561 Reduced 5.46%
373,368 $6.41 Million
Q1 2021

May 14, 2021

SELL
$16.56 - $25.46 $489,761 - $752,979
-29,575 Reduced 6.97%
394,929 $7.9 Million
Q4 2020

Feb 12, 2021

SELL
$15.77 - $19.03 $827,925 - $999,075
-52,500 Reduced 11.01%
424,504 $7.22 Million
Q3 2020

Nov 13, 2020

SELL
$16.59 - $24.79 $275,095 - $411,067
-16,582 Reduced 3.36%
477,004 $7.91 Million
Q2 2020

Aug 14, 2020

SELL
$16.86 - $23.44 $3.08 Million - $4.29 Million
-182,910 Reduced 27.04%
493,586 $11.4 Million
Q1 2020

May 15, 2020

BUY
$14.47 - $27.96 $5.92 Million - $11.4 Million
409,366 Added 153.25%
676,496 $12.1 Million
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $1.7 Million - $2.48 Million
-107,225 Reduced 28.64%
267,130 $5.77 Million
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $2.61 Million - $5.59 Million
154,065 Added 69.94%
374,355 $6.82 Million
Q2 2019

Aug 14, 2019

BUY
$31.0 - $36.3 $6.83 Million - $8 Million
220,290 New
220,290 $7.84 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $169M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Osterweis Capital Management Inc Portfolio

Follow Osterweis Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Osterweis Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Osterweis Capital Management Inc with notifications on news.